Seminars in Radiation Oncology
Volume 19, Issue 2 , Pages 96-105 , April 2009

Cancer Stem Cells and Tumor Response to Therapy: Current Problems and Future Prospects

  • Luka Milas, MD, PhD

      Affiliations

    • Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston TX
    • Corresponding Author InformationAddress reprint requests to Luka Milas, MD, PhD, Department of Experimental Radiation Oncology-066 U. T. M.D. Anderson. Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
    • ,
  • Walter N. Hittelman, PhD

      Affiliations

    • Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston TX

References 

  1. Ang KK, Peters LJ, Weber RS, et al. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys. 1990;19:1339–1345
  2. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16
  3. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomized multicentre trial. Radiother Oncol. 1999;52:137–148
  4. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  5. Eisbruch A. Intensity-modulated therapy: A clinical perspective (Introduction). Semin Radiat Oncol. 2002;197–198
  6. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–1261
  7. Houghton J, Morozov A, Smirnova I, et al. Stem cells and cancer. Semin Cancer Biol. 2007;17:191–203
  8. Bissell MJ, LaBarge MA. Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment?. Cancer Cells. 2005;7:17–23
  9. Jones DL, Wagers AJ. No place like home: Anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol. 2008;9:11–21
  10. Morrison SJ, Spradling AC. Stem cells and niches: Mechanisms that promote stem cell maintenance throughout life. Cell. 2008;132:598–611
  11. Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment—Tumorigenesis and therapy. Nat Rev Cancer. 2005;5:867–875
  12. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008;8:545–554
  13. Wicha MS, Liu S, Dontu G. Cancer stem cells: An old idea—A paradigm shift. Cancer Res. 2006;66:1883–1890
  14. Hill RP. Identifying cancer stem cells in solid tumors: Case not proven. Cancer Res. 2006;66:1891–1896
  15. Tannock IF. Tumor physiology and drug resistance. Cancer Metastasis Rev. 2001;20:123–132
  16. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumors clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  17. Buick RN. Radiological and clinical implications of the stem cell concept in human malignancy. In:  Cory JG,  Szentivany A editor. Cancer Biology and Therapeutics. New York, NY: Plenum Publishing; 1987;p. 65–76
  18. Shelby P, Buick RN, Tannock I. A critical appraisal of the “human tumor stem-cell assay. ” N Engl J Med. 1983;308:129–134
  19. Hill RP, Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys. 1989;16:513–518
  20. Baumann M, Dorr W, Petersen C, et al. Repopulation during fractionated radiotherapy: Much has been learned, even more is open. Int J Radiat Biol. 2003;79:465–467
  21. Kern SE, Shibata D. The fuzzy math of solid tumor stem cells: A perspective. Cancer Res. 2007;67:8985–8988
  22. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones?. Cancer Res. 2008;68:4018–4021
  23. Revesz L. Effect of lethally damaged tumor cells upon the development of admixed viable cells. J Natl Cancer Inst. 1958;20:1157–1186
  24. Hewitt H, Blake E, Porter E. The effect of lethally irradiated cells on the transplantability of murine tumours. Br J Cancer. 1973;28:123–135
  25. Milas L, Ito H, Hunter N, et al. Retardation of tumor growth in mice caused by radiation-induced injury of tumor bed stoma: Dependency on tumor type. Cancer Res. 1986;46:712–727
  26. Milas L, Peters LJ. Conditioning of tissues for metastasis formation by radiation and cytotoxic drugs. In:  Nicholson GL,  Milas L editor. Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. New York, NY: Raven Press; 1984;p. 321–336
  27. Li L, Neaves WB. Normal stem cells and cancer stem cells: The niche matters. Cancer Res. 2006;66:4553–4557
  28. Polyak K, Hahn WC. Roots and stems: Stem cells in cancer. Nat Med. 2006;12:296–300
  29. Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: Turning over new leaves. Cell. 2007;128:445–458
  30. Fletcher GH. Textbook of Radiotherapy. Philadelphia, PA: Lea & Febiger; 1980;
  31. Milas L, Yamada S, Hunter N, et al. Changes in TCD50 as a measure of clonogen doubling time in irradiated and unirradiated tumors. Int J Radiat Oncol Biol Phys. 1991;21:1195–1202
  32. Milas L, Nakayama T, Hunter N, et al. Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Radiother Oncol. 1994;30:247–253
  33. Thames HD, Ruifrock AC, Milas L, et al. Accelerated repopulation during fractionated irradiation of a murine ovarian carcinoma: Downregulation of apoptosis as a possible mechanism. Int J Radiat Oncol Biol Phys. 1996;35:951–962
  34. Peters LJ, Ang KK. The role of altered fractionation in head and neck cancers. Semin Radiat Oncol. 1992;2:18–194
  35. O'Brien CA, Pollet A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–110
  36. Bickenbach JR, Chism E. Selection and extended growth of murine epidermal stem cells in culture. Exp Cell Res. 1998;244:184–195
  37. Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in Vivo. J Exp Med. 1996;193:1797–1806
  38. Jordan CT. Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol. 2004;16:708–712
  39. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breat cancer cells. PNAS. 2003;100:3983–3988
  40. Molofsky AV, Pardal R, Morrison SJ. Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol. 2004;16:700–707
  41. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–5828
  42. Hammati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100:15178–15183
  43. Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12:1167–1174
  44. Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: Stem cells, signals and combinatorial control. Nat Rev Genet. 2006;7:349–359
  45. Williams DA, Cancelas JA. Leukaemia: Niche retreats for stem cells. Nature. 2006;444:827–828
  46. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432:324–331
  47. Henrique D, Hirsinger E, Adam U, et al. Maintenance of neuroepithelial progenitor cells by delta-notch signaling in the embryonic chick retina. Curr Biol. 1997;7:661–670
  48. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the hematopoietic stem cell niche. Nature. 2003;435:841–846
  49. Battle E, Henderson JT, Beghtel H, et al. β-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell. 2002;111:251–263
  50. Van de Wetering M, Sancho E, Verweij C, et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002;111:241–250
  51. Lai K, Kaspar BK, Gage FH, et al. Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci. 2003;6:21–27
  52. Kai T, Spradling A. An empty drosophila stem cell niche reactivates the proliferation of ectopic cells. Proc Natl Acad Sci U S A. 2003;100:4633–4638
  53. Evangelista M, Tian H, de Sauvage J. The hedgehog signaling pathway in cancer. Clin Cancer Res. 2006;12:5924–5928
  54. Hall EJ. Radiobiology for the Radiologist. ed 5. New York, NY: Lippincott Williams & Wilkins; 2000;
  55. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129:465–472
  56. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760
  57. Rich J. Cancer stem cells in radiation resistance. Cancer Res. 2007;67:8980–8984
  58. Hambardzumyan D, Becher OJ, Rosenblum MK, et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008;22:436–448
  59. Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol. 2007;435:297–321
  60. Hardee ME, Arcasoy MO, Blackwell KL, et al. Erythropoietin biology in cancer. Clin Cancer Res. 2006;12:332–339
  61. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285:1182–1186
  62. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364
  63. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–974
  64. Kerbel RS. Antiangiogenic therapy: A universal chemosensitization strategy for cancer?. Science. 2006;312:1171–1175
  65. Teicher BA, Holden SA, Dupuis NP, et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat. 1995;36:227–236
  66. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest N Drugs. 1997;15:39–48
  67. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: A new paradigm for combination therapy. Nat Med. 2001;7:987–989
  68. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoitin-1, and matrix metalloproteinases. Cancer Cells. 2004;6:553–563
  69. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res. 2005;11:743–750
  70. Huber PE, Bischof M, Jenne J, et al. Trimodel cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 2005;65:3643–3655
  71. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–1804
  72. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–1143
  73. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  74. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol. 2008;26:175–176
  75. Baselga J. Targeting tyrosine kinases in cancer: The second wave. Science. 2006;312:1175–1178
  76. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res. 2007;13:1955–1960
  77. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435:1267–1270
  78. Milas L, Mason KA, Ang KK. Epidermal growth factor receptor and its inhibition in radiotherapy: In-vivo findings. Int J Radiat Biol. 2003;79:539–545
  79. Schmidt-Ullrich RK, Dent P, Grant S, et al. Signal transduction and cellular radiation responses. Radiat Res. 2000;153:245–257
  80. Schmidt-Ullrich RK, Mikkelsen RBDent P, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997;15:1191–1197
  81. Milas L, Mason K, Hunter N, et al. In-vivo enhancement of tumor radio response by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000;6:701–708
  82. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000;6:2166–2174
  83. Mendelsohn J. Blockade of receptors for growth factors: An anticancer therapy (The fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Research award lecture). Clin Cancer Res. 2000;6:747–753
  84. Nasu S, Ang KK, Fan Z, et al. C225 antiepidermal growth factor receptor antibody enhances tumor radio curability. Int Radiat Oncol J Biol Phys. 2001;51:474–477
  85. Raben D, Bianco C, Milas L, et al. Targeted therapies and radiation for the treatment of head and neck cancer: Are we making progress?. Semin Radiat Oncol. 2004;14:139–152
  86. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  87. Krause M, Ostermann G, Petersen C, et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol. 2005;76:162–167
  88. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005;280:31182–31189
  89. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–1355
  90. Milas L, Akimoto T, Hunter NR, et al. Relationship between cyclin D1 expression and poor radio response of murine carcinomas. Int J Radiat Oncol Biol Phys. 2002;52:514–521
  91. Mason KA, Hunter NR, Raju U, et al. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radio response. Int J Radiat Oncol Biol Phys. 2004;59:1181–1189
  92. Raju U, Nakata E, Mason KA, et al. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res. 2003;63:3263–3267
  93. Sedlacek HH. Mechanisms of action of flavopiridol (Crit). Rev Oncol. 2001;38:139–170
  94. Chen YJ, Sims-Mourtada J, Izzo J, et al. Targeting the hedgehog pathway to mitigate treatment resistance. Cell Cycle. 2007;6:1826–1830
  95. Zhu GY, Cao XY, Chang JY, et al. Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol Rep. 2007;18:645–651
  96. Urano U, Suit H. Experimental evaluation of tumor bed effect of C3H mouse mammary carcinoma and for C3H mouse fibrosarcoma. Radiat Res. 1970;45:41–49
  97. Milas L, Hunter N, Peters LJ. The tumor bed effect: Dependence of tumor take, growth rate, and metastasis on the time interval between irradiation and tumor cell transplantation. Int J Radiat Oncol Biol Phys. 1987;13:379–383
  98. Milas L. Tumor bed effect in murine tumors: Relationship to tumor take and tumor macrophage content. Radiat Res. 1990;123:232–236
  99. Riesterer O, Pickett J, Patel N, et al. Tumor bed irradiation enhances sensitivity of A431 tumor xenografts to C225 anti-EGFR antibody. Proc Am Assoc Cancer Res. 2008;49:abstr. No. 1318
  100. Tredan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–1154
  101. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  102. Hicklin DJ, Ellis LM. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1127
  103. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol. 1994;59:471–482
  104. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2:689–692
  105. Milas L, Fang FM, Mason KA, et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys. 2007;67:568–572
  106. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A Rational Advance?. J Natl Cancer Inst. 2003;95:1440–1452
  107. Milas L, Furuta Y, Hunter N, et al. Dependence of indomethacin-induced potentiation of murine tumor radio response on tumor host immunocompetence. Cancer Res. 1990;50:4473–4477
  108. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep. 1964;35:1–111

 Supported by NCI Grants CA-06294, CA-106451, CA-103830, CA-16672, DE 13,157, DAMD 17-02-1-0706, and DAMD 17-1-1-0689.

PII: S1053-4296(08)00080-5

doi: 10.1016/j.semradonc.2008.11.004

Seminars in Radiation Oncology
Volume 19, Issue 2 , Pages 96-105 , April 2009

Article Tools

* Image Usage & Resolution